MY ABPI LOGIN
 
Tags - UK and EU future relationship

Patients must get the medicine they need after Brexit

Making sure patients continue to get the medicines they need is of upmost importance as we negotiate the UK’s withdrawal from the EU. 

Preparing for Brexit: ABPI’s reaction to MHRA update for pharma

As the MHRA publishes an update to pharmaceutical companies on preparing for Brexit, the ABPI reaffirms the importance of patient and public health in negotiations.

UK pharma welcomes positive progression in Brexit talks

The Association of the British Pharmaceutical Industry (ABPI) - representing leading global pharmaceutical businesses in the UK - have welcomed the EU Council's agreement to progress Brexit negotiations to the next phase and the EU Council's approval of a transition period.

Pharmaceutical industry responds to Trade Bill amendment on medicines

Parliament has voted in favour of amendment NC17 to the Trade Bill that will make it a negotiating objective for the UK Government to seek the UK's participation in the European medicines regulatory network.

Pharmaceutical industry reaction to Brexit White Paper

The UK government have today published a White Paper detailing their position on ‘The Future Relationship between the United Kingdom and the European Union’.

Industry backs findings of new Health and Social Care Committee report into Brexit

Responding to a new House of Commons Health and Social Care Select Committee report ‘Brexit – Medicines, Medical Devices and Substances of Human Origin’, the trade associations representing the UK's pharmaceutical and biotech industries have issued a joint response backing the Committee's...

New verification system will secure patient safety and support continuation of medicines supply

UK Marketing Authorisation Holders urged to register with SecurMed UK

The pharmaceutical industry response to the Prime Minister’s 'Road to Brexit' speech

The ABPI has responded to the Prime Minister's ‘Road to Brexit’ speech today at Mansion House.

Our view: Redistribution of UK’s portfolio of centrally authorised products

Last week, the EMA announced it has completed the reallocation of the medicines for which the UK's national regulator - the MHRA - is currently rapporteur or co-rapporteur appointed by the scientific committees to coordinate the evaluation of a medicine.

ABPI and BIA input to MHRA consultation on EU Exit 'no deal' contingency legislation for the regulation of medicines and medical devices

The ABPI and BIA have submitted a joint submission in response to the MHRA and DHSC consultation on 'no deal' contingency legislation for medicines and devices regulation for the UK.

Industry response to Simon Stevens’ comments on the Andrew Marr show

Simon Stevens appeared on the Andrew Marr Show on Sunday 1 July and was asked about preparations for Brexit and contingency planning for a no-deal scenario to ensure the continued supply of medicines to the UK.

;